Akebia Therapeutics Business Summary

Akebia Therapeutics, Inc. (AKBA) is a fully integrated biopharmaceutical company that generates revenue primarily through the commercialization of its nephrology portfolio and strategic licensing agreements. Its primary revenue drivers are Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for dialysis-dependent anemia, and Auryxia (ferric citrate), a phosphate binder and iron deficiency treatment. The company operates through two main functional segments: its commercial-stage renal franchise and an expanding R&D pipeline focused on rare kidney diseases, including candidates like praliciguat and AKB-097. Akebia competes directly with GSK (Jesduvroq), AstraZeneca (Evrenzo), FibroGen, and Amgen (Epogen/Aranesp), positioning itself as a specialized leader in oral alternatives to traditional injectable erythropoiesis-stimulating agents (ESAs) within the dialysis market. Leadership is spearheaded by President and CEO John P. Butler, who brings over three decades of industry experience from Genzyme and Inspiration Biopharmaceuticals. The executive team includes Erik Ostrowski as CFO and Chief Business Officer, Steven K. Burke, M.D., as Chief Medical Officer, and Kimberly Garko as Chief Technical Officer. Akebia was co-founded by Robert Shalwitz and Joseph Gardner, leveraging a pedigree in metabolic and renal research. The company’s Board of Directors is chaired by Adrian Adams and features notable industry veterans such as LeAnne M. Zumwalt, a former executive at DaVita Inc., and Dr. Myles Wolf of Weill Cornell Medicine. Major institutional backing has historically included prominent life science investors such as Novo Holdings and the Novartis Venture Fund.